UP!

SPPI $1.03

SPPI target price
1.03
0
0
Spectrum Pharmaceuticals
Type
Public
Traded as NASDAQ: SPPI
S&P 600 Component
Industry Pharmaceuticals
Headquarters Henderson, Nevada
Key people
R. Shrotriya, Chief Executive Officer
Website www.spectrumpharm.com

Spectrum Pharmaceuticals is an American biopharmaceutical company. The company is located in Irvine, California.

Spectrum develops and markets drugs for treatments in oncology.

A number of drugs are currently investigated in clinical trials.

Spectrum terminated the development of Ozarelix, a luteinizing hormone releasing hormone antagonist for the treatment of benign prostatic hypertrophy in 2010. Other previous drug candidates included ortataxel for the treatment of taxane-refractory tumors, and satraplatin for non-small cell lung cancer.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2022 2022-11-08 Future report Set alerts
Q2 2022 2022-08-11 -0.17 -0.17
Q1 2022 2022-05-12 -0.09 -0.09
Q4 2021 2022-03-17 -0.26 -0.26
Q3 2021 2021-11-10 -0.21 -0.21
Q2 2021 2021-08-12 0.00 0.00
Q1 2021 2021-05-13 -0.25 -0.25
Q4 2020 2021-03-30 -0.29 -0.29
Q3 2020 2020-11-04 -0.37 -0.37
Q2 2020 2020-08-10 -0.28 -0.29

Ratings

2016-05-09 Reiterated Rating Jefferies Group Hold $5.00 to $6.00
2016-03-15 Reiterated Rating FBR & Co. Outperform $10.00
2016-03-15 Reiterated Rating FBR & Co Outperform $10.00
2016-03-14 Reiterated Rating HC Wainwright Buy
2016-03-09 Reiterated Rating FBR & Co. Outperform
2016-02-26 Reiterated Rating Jefferies Group Hold $5.00
2016-02-17 Reiterated Rating Jefferies Hold $6.00 to $5.00
2016-02-17 Reiterated Rating Jefferies Group Hold $6.00 to $5.00
2016-02-16 Lower Price Target Jefferies Group Hold $6.00 to $5.00
2015-11-05 Lower Price Target RBC Capital Outperform $13.00 to $12.00
2015-11-05 Lower Price Target Royal Bank Of Canada Outperform $13.00 to $12.00
2015-10-27 Reiterated Rating HC Wainwright Buy
2015-10-23 Reiterated Rating RBC Capital Buy $13.00
2015-08-18 Reiterated Rating Roth Capital Neutral $6.00
2015-08-07 Boost Price Target RBC Capital Outperform $12.00 to $13.00
2015-06-29 Initiated Coverage HC Wainwright Buy $10.00
2015-06-05 Reiterated Rating HC Wainwright Buy
2015-05-16 Reiterated Rating HC Wainwright Buy $13.00 to $10.00
2015-04-01 Initiated Coverage FBR & Co. Outperform $9.00
2015-03-16 Lower Price Target Jefferies Group Hold $8.00 to $6.00
2015-02-26 Set Price Target Roth Capital Hold $7.00
2015-02-23 Set Price Target HC Wainwright Buy $15.00
2015-02-23 Downgrade Roth Capital Buy to Neutral $15.00 to $7.00
2014-11-19 Initiated Coverage Jefferies Group Hold $8.00
2014-07-15 Boost Price Target R. F. Lafferty Sell to Neutral $7.50
2014-07-07 Reiterated Rating Roth Capital Positive
2014-02-06 Reiterated Rating Roth Capital Buy
2013-10-07 Initiated Coverage HC Wainwright Buy $15.00
2013-05-29 Initiated Burrill Institutional Research Mkt Outperform $12
2013-03-13 Downgrade WallachBeth Buy to Sell $20 to $5.50
2011-05-02 Reiterated MLV Capital Buy $12.50 to $20.50
2011-03-25 Initiated RBC Capital Mkts Outperform $12
2010-12-07 Reiterated Morgan Joseph Buy $8 to $10
2010-01-12 Upgrade Morgan Joseph Hold to Buy $8
2009-10-14 Reiterated Rodman & Renshaw Mkt Outperform $10 to $8
2009-09-08 Downgrade Morgan Joseph Buy to Hold
2008-09-09 Initiated Morgan Joseph Buy $5
2008-04-23 Downgrade Oppenheimer Outperform to Perform
2008-03-18 Downgrade Brean Murray Buy to Hold
2007-10-31 Reiterated Rodman & Renshaw Mkt Outperform $8 to $6
2007-07-25 Upgrade Brean Murray Sell to Hold
2007-07-25 Reiterated Lazard Capital Buy $11 to $6
2007-07-25 Downgrade Friedman Billings Outperform to Mkt Perform $12.25 to $5.50
2007-07-23 Downgrade Brean Murray Buy to Sell $11 to $4
2016-05-09 Reiterated Rating Jefferies Group Hold $5.00 to $6.00
2016-03-15 Reiterated Rating FBR & Co. Outperform $10.00
2016-03-15 Reiterated Rating FBR & Co Outperform $10.00
2016-03-14 Reiterated Rating HC Wainwright Buy
2016-03-09 Reiterated Rating FBR & Co. Outperform

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In SPPI 0 funds of 2213 total. Show all

Fund name Ticker shares

Major Shareholders

Name Relationship Total Shares Holding stocks
SHROTRIYA RAJESH C MD Chairman, CEO & President 1.20%  (789977) ENMD / SPPI /
Turgeon Joseph W. Chief Commercial Officer 0.48%  (316509) SPPI /
Riga Thomas J Chief Operating Officer 0.37%  (243854) SPPI /
KUMARIA SHYAM K Sr. Vice President Finance 0.33%  (218471) SPPI /
GUSTAFSON KURT A EVP & Chief Financial Officer 0.28%  (187193) HALO / SPPI / XNCR /
Keller Joseph Kenneth EVP & Chief Operating Officer 0.26%  (168000) SPPI /
Shields James Chief Commercial Officer 0.13%  (87806) SPPI /
Gagnon Gilles 0.13%  (82500) SPPI /
ALLEN LEE F MD PhD Chief Medical Officer 0.12%  (80381) AMAG / ARGS / SPPI /
Krassner Stuart Mitchell 0.12%  (79057) SPPI /
LENAZ LUIGI MD 0.11%  (69077) SPPI /
Scott Brett L Acting Chief Financial Officer 0.07%  (45661) BIOL / SPPI /
COHEN RAYMOND W 0.07%  (43125) BLFS / SPPI /
TIDMARSH GEORGE F CSO AND HEAD OF R&D OPERATIONS 0.06%  (40000) LJPC / SPPI /
Vyas Dolatrai 0.06%  (37079) SPPI /
MEHTA DILIP J MD PHD 0.05%  (32000) SPPI /
MAIDA ANTHONY E III 0.03%  (22988) ONCS / SPPI /
Arora Krishan K 0.02%  (15000) SPPI /
GUETH ANTON 0.02%  (11000) ATRS / NAVB / SPPI /